Literature DB >> 8204374

Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days.

T J O'Rourke, T D Brown, K Havlin, J G Kuhn, J B Craig, H A Burris, W G Satterlee, P G Tarassoff, D D Von Hoff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8204374     DOI： 10.1016/0959-8049(94)90276-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  12 in total

1.  A phase I trial of gemcitabine administered as a 96-h continuous intravenous infusion in patients with advanced carcinoma and lymphoma.

Authors:  Lakshmi Rajdev; Gary Goldberg; Una Hopkins; Joseph A Sparano
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  A 21-day schedule of gemcitabine and cisplatin administration in the treatment of advanced non-small cell lung carcinoma: a phase II study.

Authors:  Jong-Sung Park; Chang-Min Lee; Shin-Ae Lee; Chang-Kil Jung; Sung-Hyun Kim; Hyuk-Chan Kwon; Jae-Seok Kim; Hyo-Jin Kim
Journal:  Cancer Res Treat       Date:  2004-02-29       Impact factor: 4.679

3.  A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors.

Authors:  R Brand; M Capadano; M Tempero
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

4.  Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: result of a dose-intensity study.

Authors:  Hector Soto Parra; Raffaele Cavina; Fiorenza Latteri; Elisabetta Campagnoli; Emanuela Morenghi; Walter Torri; Giorgio Brambilla; Marco Alloisio; Armando Santoro
Journal:  Invest New Drugs       Date:  2007-02       Impact factor: 3.850

5.  Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team.

Authors:  D D Von Hoff
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

6.  Gemcitabine single or combination chemotherapy in post anthracycline and taxane salvage treatment of metastatic breast cancer: retrospective analysis of 124 patients.

Authors:  Min Kyoung Kim; Sung-Bae Kim; Jin Hee Ahn; Soon Im Lee; Sei-Hyun Ahn; Byung Ho Son; Gyungyub Gong; Hak-Hee Kim; Jung-Shin Lee; Yoon-Koo Kang; Woo Kun Kim
Journal:  Cancer Res Treat       Date:  2006-12-31       Impact factor: 4.679

7.  A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer.

Authors:  H Anderson; N Thatcher; J Walling; H Hansen
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

Review 8.  Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.

Authors:  D D Von Hoff; A L Goodwin; L Garcia
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

9.  Interleukin 6 is a cause of flu-like symptoms in treatment with a deoxycytidine analogue.

Authors:  N Masuda; S Negoro; K Takeda; N Kurata; T Kuwabara; S Kobayashi; M Fukuoka
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

10.  Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma.

Authors:  C Bengala; V Guarneri; E Giovannetti; M Lencioni; E Fontana; V Mey; A Fontana; U Boggi; M Del Chiaro; R Danesi; S Ricci; F Mosca; M Del Tacca; P F Conte
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.